Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)

NCT02116660 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

11

Enrollment

INDUSTRY

Sponsor class

Stopped This study was terminated early due to poor recruitment.

Conditions

HIV Infections

Interventions

DRUG: Raltegravir (MK-0518)
DRUG: Nevirapine
DRUG: Lamivudine
DRUG: Tenofovir
DRUG: Emtricitabine
DRUG: Lopinavir
DRUG: Ritonavir
DRUG: Atazanavir
DRUG: Darunavir

Sponsor

Merck Sharp & Dohme LLC